Answers are grounded in this paper and cite their sources.
This study suggests no impact of neutropenia-related treatment modifications on PFS and confirms inferior outcomes outside clinical trial eligibility.
No takes yet. Share an insight, caveat, or question.
Hackert et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: